|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-10-16
|
|
pubmed:abstractText |
Intensive chemotherapy produces a lower complete remission (CR) rate in the myelodysplastic syndromes (MDS) than in de novo acute myeloid leukaemia (AML), possibly due in part to a higher incidence of P glycoprotein (PGP) expression in MDS blast cells. We designed a randomized trial of intensive chemotherapy with or without quinine, an agent capable of reverting the multidrug resistance (mdr) phenotype, in patients aged < or = 65 years with high-risk MDS. Patients were randomized to receive mitoxantrone 12 mg/m2/d days 2-5 + AraC 1 g/m2/12 h days 1-5, with (Q+) or without (Q-) quinine (30 mg/kg/d). 131 patients were included. PGP expression analysis was successful in 91 patients. In the 42 PGP-positive cases, 13/25 (52%) patients in the Q+ group achieved CR, compared to 3/17 (18%) patients in the Q- group (P = 0.02) and median Kaplan-Meier survival was 13 months in the Q+ group, and 8 months in the Q- group (P = 0.01). No life-threatening toxicity was observed with quinine. In conclusion, the results of this randomized study show that quinine increases the CR rate and survival in PGP-positive MDS cases treated with intensive chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
pubmed-author:BricePP,
pubmed-author:BrionAA,
pubmed-author:BuzynAA,
pubmed-author:CaillotDD,
pubmed-author:CordonnierCC,
pubmed-author:DesablensBB,
pubmed-author:DreyfusFF,
pubmed-author:FenauxPP,
pubmed-author:GratecosNN,
pubmed-author:GuerciAA,
pubmed-author:HecquetBB,
pubmed-author:Hoang-NgocLL,
pubmed-author:IfrahNN,
pubmed-author:JanvierMM,
pubmed-author:LioureBB,
pubmed-author:MalmBB,
pubmed-author:MaloiselFF,
pubmed-author:MilpiedNN,
pubmed-author:RochantHH,
pubmed-author:SadounAA,
pubmed-author:SolaryEE,
pubmed-author:StamatoulasAA,
pubmed-author:StoppaA MAM,
pubmed-author:TillyHH,
pubmed-author:WattelEE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1015-24
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9734653-Adult,
pubmed-meshheading:9734653-Aged,
pubmed-meshheading:9734653-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9734653-Cytarabine,
pubmed-meshheading:9734653-Drug Resistance, Neoplasm,
pubmed-meshheading:9734653-Drug Therapy, Combination,
pubmed-meshheading:9734653-Female,
pubmed-meshheading:9734653-Follow-Up Studies,
pubmed-meshheading:9734653-Humans,
pubmed-meshheading:9734653-Male,
pubmed-meshheading:9734653-Middle Aged,
pubmed-meshheading:9734653-Mitoxantrone,
pubmed-meshheading:9734653-Myelodysplastic Syndromes,
pubmed-meshheading:9734653-Neoplasm Proteins,
pubmed-meshheading:9734653-P-Glycoprotein,
pubmed-meshheading:9734653-Quinine,
pubmed-meshheading:9734653-Survival Rate,
pubmed-meshheading:9734653-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
|
|
pubmed:affiliation |
Groupe Français des Myélodysplasies, Service des Maladies du Sang, CHU, Lille, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
